A Study of LY3561774 in Participants With Dyslipidemia
Status:
Recruiting
Trial end date:
2022-04-28
Target enrollment:
Participant gender:
Summary
This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and
tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high
blood fat levels). How the body processes the study drug and the effect of the study drug on
blood fat levels will also be investigated. Part C will mainly evaluate the safety and
tolerability of LY3561774 as well as how the body processes the study drug in Japanese
participants. The study may last up 52, 56 and 28 weeks for each participant in Parts A, B
and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.